Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity

Authors: Yang S.P.; Ho L.J.; Lin Y.L.; Cheng S.M.; Tsao T.P.; Chang D.M.; Hsu Y.L.; Shih C.Y.; Juan T.Y.; Lai J.H.1

Source: Cardiovascular Research, Volume 59, Number 3, 1 September 2003 , pp. 776-787(12)

Publisher: Elsevier

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Carvedilol; Atherosclerosis; T cells; Cytokines; NF-kappaB

Language: English

Document Type: Research article

DOI: 10.1016/S0008-6363(03)00459-0

Affiliations: 1: Rheumatology/Immunology and Allergy, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Rd., Neihu 114, , Taipei, Taiwan, ROC

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A